The rate of HIV transmission per coital act was highest during early-stage infection. This has implications for HIV prevention and for projecting the effects of antiretroviral treatment on HIV transmission.
BACKGROUND
Male circumcision significantly reduced the incidence of human immunodeficiency virus (HIV) infection among men in three clinical trials. We assessed the efficacy of male circumcision for the prevention of herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) infections and syphilis in HIV-negative adolescent boys and men.
METHODS
We enrolled 5534 HIV-negative, uncircumcised male subjects between the ages of 15 and 49 years in two trials of male circumcision for the prevention of HIV and other sexually transmitted infections. Of these subjects, 3393 (61.3%) were HSV-2–seronegative at enrollment. Of the seronegative subjects, 1684 had been randomly assigned to undergo immediate circumcision (intervention group) and 1709 to undergo circumcision after 24 months (control group). At baseline and at 6, 12, and 24 months, we tested subjects for HSV-2 and HIV infection and syphilis, along with performing physical examinations and conducting interviews. In addition, we evaluated a subgroup of subjects for HPV infection at baseline and at 24 months.
RESULTS
At 24 months, the cumulative probability of HSV-2 seroconversion was 7.8% in the intervention group and 10.3% in the control group (adjusted hazard ratio in the intervention group, 0.72; 95% confidence interval [CI], 0.56 to 0.92; P = 0.008). The prevalence of high-risk HPV genotypes was 18.0% in the intervention group and 27.9% in the control group (adjusted risk ratio, 0.65; 95% CI, 0.46 to 0.90; P = 0.009). However, no significant difference between the two study groups was observed in the incidence of syphilis (adjusted hazard ratio, 1.10; 95% CI, 0.75 to 1.65; P = 0.44).
CONCLUSIONS
In addition to decreasing the incidence of HIV infection, male circumcision significantly reduced the incidence of HSV-2 infection and the prevalence of HPV infection, findings that underscore the potential public health benefits of the procedure.
Background-A randomized trial of male circumcision (MC) was conducted among HIVinfected males to test the hypothesis that MC would reduce HIV transmission to female sexual partners.
HIV disease progression is affected by HIV-1 subtype. This finding may impact decisions on when to initiate antiretroviral therapy and may have implications for future trials of HIV-1 vaccines aimed at slowing disease progression.
BACKGROUNDTo assess the impact of combination HIV prevention (CHP) on HIV incidence, we analyzed the
association between HIV incidence and scale-up of antiretroviral therapy (ART) and medical
male circumcision in Rakai, Uganda. Changes in population-level viral load suppression and
sexual behaviors were also examined.METHODSBetween 1999 and 2016, data were collected through 12 surveys from 30 communities in the
Rakai Community Cohort Study, an open population-based cohort of persons aged 15-49 years.
We assessed HIV incidence trends based on observed seroconversion data, self-reported ART
and male circumcision coverage, viral load suppression, and sexual behaviors.RESULTSIn total, 33,937 study participants contributed 103,011 person-visits (HIV prevalence ~13%).
Follow-up of 17,870 HIV-negative persons contributed 94,427 person-years with 931
seroconversions. ART was introduced in 2004; by 2016 coverage was 69% (72% in women vs.
61% in men, p<0.001). HIV viral load suppression among all HIV-positive persons increased
from 42% in 2009 to 75% by 2016 (p<0.001). Male circumcision coverage increased from 15%
in 1999 to 59% by 2016 (p<0.001). Persons 15-19 years reporting n 71 ever having sex increased
from 30% to 55% (p<0.0001). HIV incidence declined by 42% in 2016 relative to the pre-CHP
period prior to 2010 (1.17/100 py to 0.66/100 py; adjIRR:0.58: 95%CI: 0.45-0.76); declines were
greater in men (adjIRR=0.46; 95%CI: 0.29-0.73) than women (adjIRR=0.68, 95%CI: 0.50-0.94).CONCLUSIONSIn this longitudinal study, HIV incidence significantly declined with CHP scale-up, providing
empiric evidence that HIV control interventions can have substantial population-level impact.
However, additional efforts are needed to overcome gender disparities and achieve HIV
elimination.
Objective-To assess effects of male circumcision on female genital symptoms, and vaginal infections.Methods-HIV-negative men enrolled in a trial were randomized to immediate or delayed circumcision (control arm). Genital symptoms, BV and trichomonas were assessed in HIV-negative wives of married participants. Adjusted prevalence risk ratios (adjPRR) and 95% confidence intervals (95%CI) were assessed by multivariable log-binomial regression, intent-to-treat analyses.Results-783 wives of control and 825 wives of intervention arm men were comparable at enrollment. BV at enrollment was higher in control (38.3%) than intervention arm spouses (30.5%, p=0.001). At one year follow up, intervention arm wives reported lower rates of genital ulceration (adjPRR 0.78, 95%CI 0.63-0.97), but there were no differences in vaginal discharge or dysuria. The risk of trichomonas was reduced in intervention arm wives (adjPRR 0.52, 95%CI 0.05-0.98), as were the risks of any BV (adjPRR 0.60, 95%CI 0.38-0.94) and severe BV (PRR = 0.39, 95%CI 0.24-0.64).Conclusions-Male circumcision reduces the risk of ulceration, trichomonas and BV in female partners.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.